WellPoint Targets Breast Cancer Patients, Drop Their Coverage

Robin Marty

Insurance company WellPoint draws fire for targeting breast cancer patients to drop their coverage, but can anyone stop them?

In another sign that healthcare reform may not be the panacea we were hoping for in guaranteeing access to health care for everyone, a recent Reuters report reveals that insurer WellPoint has been systematically targeting recent breast cancer patients and dropping them from insurance coverage.  This practice, known as rescission, was one that was supposed to be addressed in the healthcare overhaul recently signed into law.  Sadly, it seems that legislation forgot to provide any real enforcement.

Many critics worry the new law will not lead to an end of these practices. Some state and federal regulators — as well as investigators, congressional staffers and academic experts — say the health care legislation lacks teeth, at least in terms of enforcement or regulatory powers to either stop or even substantially reduce rescission.

“People have this idea that someone is going to flip a switch and rescission and other bad insurance practices are going to end,” says Peter Harbage, a former health care adviser to the Clinton administration. “Insurers will find ways to undermine the protections in the new law, just as they did with the old law. Enforcement is the key.”

Like This Story?

Your $10 tax-deductible contribution helps support our research, reporting, and analysis.

Donate Now

During the recent legislative process for the reform law, however, lobbyists for WellPoint and other top insurance companies successfully fought proposed provisions of the legislation. In particular, they complained about rules that would have made it more difficult for the companies to fairly — or unfairly — cancel policyholders.

For example, an early version of the health care bill passed by the House of Representatives would have created a Federal Office of Health Insurance Oversight to monitor and regulate insurance practices like rescission. WellPoint lobbyists pressed for the proposed agency to not be included in the final bill signed into law by the president.

They also helped quash proposed provisions that would have required a third party review of its or any other insurance company’s decision to cancel a customer’s policy.

As Firedog Lake reports, it wasn’t just a matter of WellPoint lobbyists influencing the bill, but writing it, too.

As Marcy Wheeler reported last year, the Senate Finance Committee bill was written by former Wellpoint VP Liz Fowler, who left her position at the insurance company in February 2009 expressly for the purpose of  working on Senate committee drafting the health care bill:

And when Max Baucus did a “victory lap” after the bill’s passage, he expressly thanked Fowler for her work:

I wish to single out one person, and that one person is sitting next to me. Her name is Liz Fowler. Liz Fowler is my chief health counsel. Liz Fowler has put my health care team together. Liz Fowler worked for me many years ago, left for the private sector, and then came back when she realized she could be there at the creation of health care reform because she wanted that to be, in a certain sense, her profession lifetime goal. She put together the White Paper last November–2008–the 87-page document which became the basis, the foundation, the blueprint from which almost all health care measures in all bills on both sides of the aisle came. She is an amazing person. She is a lawyer; she is a Ph.D. She is just so decent. She is always smiling, she is always working, always available to help any Senator, any staff. I thank Liz from the bottom of my heart. In many ways, she typifies, she represents all of the people who have worked so hard to make this bill such a great accomplishment.

Susan Bayh, wife of Indiana Senator Evan Bayh, is on the Wellpoint board.  Bayh threatened to join Joe Lieberman in a filibuster of the health care bill if a public option was included, something that would very much threaten Wellpoint profits — which have soared in the past year.   Susan Bayh’s compensation for her role on the Wellpoint board includes valuable stock options.

The fact that the health care bill was written by Wellpoint for the benefit of Wellpoint is bad enough. The fact that Max Baucus celebrates that fact is worse.  And the fact that Wellpoint jammed it through with the help of Evan Bayh, who is adding to his personal fortune at the expense of breast cancer patients, is absolutely despicable.

The breast cancer investigation reveals something that many of us have suspected for quite some time: insurance companies hate covering women due to the myriad of costs we can incur, both on our own and because we have families.

“It’s not like these companies don’t like women because they are women,” says Jeff Isaacs, the chief assistant Los Angeles City Attorney who runs the office’s 300-lawyer criminal division. “But there are two things that really scare them and they are breast cancer and pregnancy. Breast cancer can really be a costly thing for them. Pregnancy is right up there too. Their worst-case scenario is that a child will be born with some disability and they will have to pay for that child’s treatment over the course of a lifetime.”

Without real regulation in reform, it looks like women are being thrown under the bus twice.  Once, by compromises of our reproductive rights to pass a bill (a now-routine “compromise”), and then again by being subjec tto continued punishment by insurers just for being women.

Analysis Abortion

From Webbed Feet to Breast Cancer, Anti-Choice ‘Experts’ Renew False Claims

Ally Boguhn & Amy Littlefield

In a series of workshops over a three-day conference in Herndon, Virginia, self-proclaimed medical and scientific experts renewed their debunked efforts to promote the purported links between abortion and a host of negative outcomes, including breast cancer and mental health problems.

Less than two weeks after the Supreme Court rejected the anti-choice movement’s unscientific claims about how abortion restrictions make patients safer, the National Right to Life Convention hosted a slate of anti-choice “experts,” who promoted even more dubious claims that fly in the face of accepted medical science.

In a series of workshops over the three-day conference in Herndon, Virginia, self-proclaimed medical and scientific experts, including several whose false claims have been exposed by Rewire, renewed their efforts to promote the purported links between abortion and a host of negative outcomes, including breast cancer and mental health problems.

Some of those who spoke at the convention were stalwarts featured in the Rewire series “False Witnesses,” which exposed the anti-choice movement’s attempts to mislead lawmakers, courts, and the public about abortion care.

One frequent claim, that abortion increases the risk of breast cancer, has been refuted by the National Cancer Institute, the American Cancer Society, and the American Congress of Obstetricians and Gynecologists. But that hasn’t stopped “experts” like Dr. Angela Lanfranchi, a breast cancer surgeon and anti-choice activist, from giving court testimonies and traveling around the world spreading that brand of misinformation.

Like This Story?

Your $10 tax-deductible contribution helps support our research, reporting, and analysis.

Donate Now

During a Thursday session titled “The Abortion-Breast Cancer Link: The Biological Basis, The Studies, and the Fraud,” Lanfranchi, one of Rewire’s “False Witnesses,” pushed her debunked talking points.

Throughout the presentation, which was attended by Rewire, Lanfranchi argued that there is “widespread fraudulent behavior among scientists and medical organizations to obfuscate the link” between abortion and breast cancer.

In a statement, the irony of which may have been lost on many in the room, Lanfranchi told attendees that sometimes “scientists in the pursuit of truth can be frauds.” Lanfranchi went on to point to numerous studies and texts she claimed supported her theories and lamented that over time, textbooks that had previously suggested a link between abortion and breast cancer in the ’90s were later updated to exclude the claim.

Lanfranchi later pivoted to note her inclusion in Rewire’s “False Witnesses” project, which she deemed an “attack.” 

“We were one of 14 people that were on this site … as liars,” said Lanfranchi as she showed a slide of the webpage. “Now when people Google my name, instead of my practice coming up,” Rewire’s story appears.

Priscilla Coleman, another “False Witness” best known for erroneously claiming that abortion causes mental health problems and drug abuse, similarly bemoaned her inclusion in Rewire’s project during her brief participation in a Thursday session, “The Conspiracy of Silence: Roadblocks to Getting Abortion Facts to the Public.”

After claiming that there is ample evidence that abortion is associated with suicide and eating disorders, Coleman suggested that many media outlets were blocking the truth by not reporting on her findings. When it came to Rewire, Coleman wrote the outlet off as a part of the “extreme left,” telling the room that “if you look deeply into their analysis of each of our backgrounds, a lot of it is lies … it’s bogus information.”

An extensive review conducted by the American Psychological Association in 2008, however, found “no evidence sufficient to support” claims such as Coleman’s that “an observed association between abortion history and mental health was caused by the abortion.”

Rounding out the medical misinformation pushed in that session was Eve Sanchez Silver, the director and founder of the International Coalition of Color for Life. According to the biography listed on her organization’s website, Silver bills herself as a “bioethicist” who focuses on “the Abortion-Breast cancer link.”

Silver, who previously worked at the Susan G. Komen Foundation but left, she said, after finding out the organization gave money to Planned Parenthood, spent much of her presentation arguing that abortion increases the risk of breast cancer. She also detailed what she referred to as the “Pink Money Cycle,” a process in which, as she explained, money is given to Komen, which in turn donates to Planned Parenthood. As Silver told it, Planned Parenthood then gives people abortions, leading to more cases of breast cancer. 

The seemingly conspiracy-driven theory has popped up in several of Silver’s presentations over the years.

Though Komen does in fact provide some funding to Planned Parenthood through grants, a July 2015 press release from the the breast cancer organization explains that it does “not and never [has] funded abortion or reproductive services at Planned Parenthood or any grantee.” Instead, the money Planned Parenthood receives from Komen “pays for breast health outreach and breast screenings for low-income, uninsured or under-insured individuals.”

On Saturday, another subject of Rewire’s “False Witnesses” series, endocrinologist Joel Brind, doubled down on his claims about the link between abortion and breast cancer in a workshop titled “New American Export to Asia: The Cover-Up of the Abortion-Breast Cancer Link.” 

Brind described the Indian subcontinent as the ideal place to study the purported link between abortion and breast cancer. According to Brind, “The typical woman [there] has gotten married as a teenager, started having kids right away, breastfeeds all of them, has lots of them, never smokes, never drinks, what else is she going to get breast cancer from? Nothing.”

When it came to research from Asia that didn’t necessarily support his conclusions about abortion and breast cancerBrind chalked it up to an international cover-up effort, “spearheaded, obviously, by our own National Cancer Institute.”

Although five states require counseling for abortion patients that includes the supposed link between abortion and breast cancer, Brind told Rewire that the link has become “the kind of thing that legislators don’t want to touch” because they would be going “against what all of these medical authorities say.” 

Brind also dedicated a portion of his presentation to promoting the purported cancer-preventing benefits of glycine, which he sells in supplement form through his company, Natural Food Science LLC. 

“If I sprain my ankle it doesn’t swell up, the injury will just heal,” Brind claimed, citing the supposed effects of glycine on inflammation. 

In a Thursday session on “the rise of the DIY abortion”, panelist Randall O’Bannon questioned the U.S. Food and Drug Administration’s (FDA) March update to regulations on mifepristone, a drug also known as RU-486 that is used in medical abortions. Noting that the drug is “cheap,” O’Bannon appeared to fret that the new regulations might make abortion more accessible, going on to claim that there could be “a push to make [the drug] available over the counter.”

O’Bannon claimed there are “documented safety issues” associated with the drug, but the FDA says mifepristone is “safe and effective.” A 2011 post-market study by the agency of those who have used the drug since its approval found that more than 1.5 million women had used it to end a pregnancy in the U.S. Of those women, just roughly 2,200 experienced an “adverse event.” According to the Association of Reproductive Health Professionals, mifepristone “is safer than acetaminophen,” aspirin, and Viagra.

Speculating that misoprostol, another drug used in medication abortions, was less effective than medical experts say, O’Bannon later suggested that more embryos would “survive” abortions, leading to an “increased numbers of births with children with club feet, webbed toes, and fingers [and] full and partial facial paralysis.”

According to the World Health Organization, “Available data regarding a potential risk of fetal abnormality after an unsuccessful medical abortion are limited and inconclusive.”

Commentary Sexual Health

What the New Breast Cancer Screening Guidelines Mean for Real-Life Women

Martha Kempner

The American Cancer Society recently released new guidelines, raising the minimum age of regular mammograms for women with no known risk factors from 40 to 45. While these guidelines may make sense when you look at population statistics as a whole, on an anecdotal level, they alarmed me as a 43-year-old.

For my 35th birthday, my gynecologist gave me a prescription for a mammogram. It was a little early, according to the American Cancer Society (ACS) guidelines at the time, but she believed a baseline mammogram was important so that radiologists would have something to compare it to in the future. When I hit 40, I got a new prescription from a new gynecologist, who told me that as someone with no other risk factors, from then on, I should get one each year.

I don’t find mammograms all that unpleasant, but I do find them scary because of the inherent “what-if-the-worst-is-true” factor: It’s easy to push it to the bottom of the to-do list instead, to instead ignore the possibility altogether.

Then I heard the story of a friend whose mammogram picked up her breast cancer. Like me, she’s 43, and she’s going through treatment now. It was enough to make me schedule the appointment. “What-if” is scary, but the prospect of having breast cancer and not knowing it is even scarier.

Just days after my all-clear results came in this time around, however, ACS released new guidelines, raising the minimum age of regular mammograms for women with no known risk factors from 40 to 45. The new recommendations are based on research showing early mammograms don’t save many lives and have the potential to cause false positives, unnecessary biopsies, and even unneeded cancer treatment.

Like This Story?

Your $10 tax-deductible contribution helps support our research, reporting, and analysis.

Donate Now

While these guidelines may make sense when you look at population statistics as a whole, on an anecdotal level, they alarmed me. As women in our early 40s, my peers and I were being bombarded with mammogram reminders as recently as last month. Suddenly, we’ve been told not to bother. In fact, we’re not supposed to screen for breast cancer at all (self-exams fell by the wayside years ago, and the new guidelines say in-office exams by doctors are not useful either). Yet, we all have friends our own age who have or have had breast cancer, and we’ve seen enough pink ribbons to remind us just how many more peers will get it in the next decades of our lives. Is it really safe to do nothing?

New Recommendations

ACS’ new guidelines were released last month in the Journal of the American Medical Association (JAMA). They suggest that women who have a normal risk of breast cancer—that is women with no family history, personal history, known genetic mutations, or other diseases that could make breast cancer more likely—can wait until 45 for a mammogram, should get one every year until 54, and then start getting them every other year for as long as they’re healthy and likely to live for ten more years.

The organization also changed its stance on clinical breast exams, which it had recommended annually starting at age 40. The new guidelines do not recommend these for women of any age, unless they have symptoms or breast abnormalities.

But ACS is not the only organization that puts out guidelines on breast cancer screening. The American Congress of Obstetricians and Gynecologists (ACOG) has its own guidelines, which suggest women get a mammogram every year or two between 40 and 49, and annually after that. The National Comprehensive Cancer Center says women should start at 40 and get one every year after that. And, the United States Preventive Services Taskforce (USPSTF) currently says, somewhat vaguely, that the decision to start mammography before age 50 should be an individual one. The recommendations issued by these groups all have varying levels of impact and influence on the medical community, insurance coverage, and public opinion as a whole.

But all of that could be changing based on current research. ACOG told the New York Times that it was going to hold a meeting in January to discuss recommendations and that the ACS would be invited. In response to ACS’s new recommendations, USPSTF said that it would examine the evidence on the cost and benefits of mammography. That group’s statement did add, however, “There are health benefits to mammography screening for women in their 40s.”

Such cautious wording may be a result of a 2009 controversy, which happened when the USPSTF revised its breast cancer screening guidelines and actually recommended against routine mammograms for women under 50. This made a lot of people very upset, because women in their 40s do get cancer and the USPSTF’s opinion on screening tests impacts whether certain tests will be covered under the Affordable Care Act (ACA). The group walked those recommendations back and said instead that women in their 40s should work with their providers to make their own screening decision and then should have annual mammograms from 50 to 74. The USPSTF released a draft of updated recommendations in May and didn’t change anything.

All of these groups review the best available data to come up with their recommendations. However, the data varies widely, both in terms of methodology and potential for interpretation. So it’s not surprising that different experts arrive at different conclusions.

The Science Behind ACS’ Guidelines

Ruth Etzioni, a statistician in the ACS Guidelines Development Group (GDG), which came up with the new recommendations, explained in an interview with Rewire, “Screening as an approach has limitations because you have to screen everybody to save a relative few.” This means that determining whether it’s worth getting screened relies on looking at population trends as a whole. No one, for example, is suggesting that all women in their 20s get regularly screened, because breast cancer is so uncommon at that age. So the panel looked at the risk of getting breast cancer, the possibility of saving lives with screening, and the downfalls of the screening itself.

The data show that the risk of getting breast cancer in the next five years is only 0.6 percent for women ages 40 to 44; it jumps to 0.9 percent for women ages 45 to 49, and 1.1 percent for those 50 to 54. But it’s not simply the risk of getting breast cancer that the panel was looking at; it’s the risk of dying from it, a fairly typical framework of evaluating the efficacy of mammograms. Many of the studies the panel examined review whether mammography at a certain age can lower the risk of death from the disease. The ACS review acknowledges that it can. The article states, “For women of all ages at average risk, screening was associated with a reduction in breast cancer mortality of approximately 20 percent.” But the number of women who will get breast cancer in their early 40s, and the percentage of those who will die from it, is still so small that it might not be worth screening everyone every year, the ACS panel determined.

Another thing the panel took into account was potential downsides of mammograms. No one is suggesting that the x-ray itself has risks. Rather, it’s what happens next—false positives, anxiety, unnecessary additional tests, and over-treatment—that has some researchers concerned. Essentially, the ACS panel determined that the risks of mammography outweighed the benefits until age 45.

According to a 2011 study, 61 percent of women who have mammograms starting at 40 are likely to have a false positive by the time they’re 50. Starting later can cut this number down, as can getting mammograms every other year. Still, the USPSTF, for example, calculated that if 1,000 women follow its current advice and have mammograms every other year from 50 to 74, 146 of them will go on to have an unnecessary breast biopsy and 18 of them will be diagnosed and treated for a cancer that would have never harmed them, which experts call “overdiagnosis.”

An editorial accompanying the JAMA article calls the review an important step forward and notes: “There is uncertainty about the magnitude of mammography’s benefits and harms and how to select patients and screening strategies to optimize the balance between benefits and harms. In the face of such uncertainty, thoughtful, evidence-based guidelines can play a powerful role in shaping policy and practice, supporting decision making by clinicians and patients, and identifying key research priorities.”

The Correct Outcomes

But some medical professionals question the new recommendations. John Cunningham, a breast surgeon with Summit Medical Group in New Jersey, told Rewire that he worries many of the standards and definitions used to judge whether widespread breast cancer screening is effective may not be giving us the right answers.

First, he explained: “I think mortality is the wrong end point. It’s hard to prove to the end result of mortality when there are so many things in between—like the course of treatment—that alter reduction of mortality.” In other words, it’s unfair to hold mammography solely responsible for saving lives, or not doing so, when the decisions made after a cancer is detected—such as how aggressively to treat it—may have more impact on a woman’s survival. Cunningham thinks that a screening test can be considered successful if it finds the disease it is screening for.

In addition, he thinks some of the additional tests that are run after something potentially suspicious is spotted on a mammogram are necessary. For the purposes of the research reviewed by ACS and other groups, every biopsy that comes back as benign is considered a false positive. Dr. Cunningham thinks this unfairly inflates the rates of false positives because sometimes biopsies find something else. “My feeling is that if it finds anything that is pathologically different than normal breast tissue it is not a true false positive,” he said. Even if it’s not cancer, it could require additional treatment, including surgery, or it could help indicate women who might be at a higher risk of developing cancer in the future.

As for overdiagnosis, or the treatment of cancer that would not have hurt patients, Cunningham thinks this label is used too much as well. Most women who fall into this category have something referred to as DCIS, ductal carcinoma in suti, which are tiny growths in the milk ducts. These may or may not become invasive cancer. Cunningham explained: “There are some patients with DCIS who would probably digress to invasive cancer if left long enough, but we don’t know whether that would be a year, ten years, or 20. Since we can’t quantify that, I don’t think we’re over-diagnosing. It’s appropriate. Then we have [to] decide what should be the management.”

Are These Results Really Harmful?

Cancer treatments are unpleasant at best and debilitating at worst. No one wants to be treated for a cancer that they could simply live with, but given that we don’t yet have the tools to know for sure which cancers will and will not become life-threatening, or how long that will take, some women might choose treatment  as the lesser of two evils. Similarly, the panel points to anxiety as one of the harms that comes from false positive tests. Certainly, the days or weeks spent between hearing that your mammogram wasn’t perfect and ultimately finding out that you don’t have cancer are going to be anxious times, but many women might feel it was worth it to know for sure.

Etzioni said she understood that this argument, but thinks women need to have more information about breast cancer and what it takes to screen everyone. She told Rewire that when it comes to individual’s health, “Breast cancer is only one of the things that we have to monitor for, and we need to have perspective. It’s not like taking your pulse or your blood pressure—mammograms, ultrasounds, MRIs, biopsies—everyone coming in to get these, it’s a huge endeavor.” And it makes sense to focus that endeavor on those most at risk. Etzioni added, “Breast cancer is just not a huge risk in your 40s.”

It is true that in absolute numbers you have to screen a lot of people to save very few; approximately five of 10,000 women in their 40s and ten of 10,000 women in the 50s are likely to have a breast cancer death prevented by regular mammography. And though mammograms are relatively inexpensive tests to conduct, nothing is inexpensive when applied to a whole population. Many experts believe that this is just not the best use of our limited health-care resources.

Outlying Stories Are Scary, But Not Typical

This argument makes a lot of sense until it comes down to the individual level—some women do get breast cancer in their 40s and do find out about it through mammography. Take the friend I mentioned in the beginning, Rachel.

“I felt something,” she said to me last week, “in the shower and thought that does not feel normal.” Rachel, like other women my age, was taught to perform self-examination once a month by standing in the shower with one arm over your head and making gentle circles all around each breast. This practice is not taught anymore because research suggested it led to false positives but didn’t necessarily save lives. Still, people our age often do it, and for Rachel it turned out to be important.

Her annual exam with her gynecologist was scheduled for the following week, so she waited and pointed it out to her doctor. The doctor didn’t feel it and said there was nothing to worry about. But Rachel was worried. Luckily, she said, she had already scheduled her annual mammogram because, at 43, she’d been following the old guidelines and was ready for her third exam.

Within half an hour of her mammogram, Rachel got a call recommending further tests, an ultrasound, and another mammogram. Ultimately, a needle biopsy confirmed that the lump was a malignant tumor.

Rachel has since had a lumpectomy and one round of chemotherapy. She’s starting another round of chemotherapy soon because they found some cancer cells in her lymph system. She has an amazing attitude about the whole thing and seems to spend no time wallowing in the “why me.” She was shaken, though, when she heard about the ACS’ new guidelines: “I was shocked and quite frankly really disappointed that the ACS would go on record suggesting that people would wait that long. If I’d waited two years, I would be terminal because that’s how aggressive this was.”

Of course, Rachel is an outlier. And as scary as her story is, it’s far from typical. Remember, there’s only a 0.6 percent risk of getting breast cancer in the next five years for someone her age.

What’s a 43-Year Old to Do?

None of the guidelines—whether they’re from ACS, ACOG, or USPSTF—are binding. Women are free to decide when they start getting mammograms and how often they get them. In fact, the newest guidelines from most of these groups encourage women to work with their providers and make their own decisions. And no one expects the ACA, which takes multiple groups’ guidelines into account, to stop covering mammograms for women in their early 40s.

I’m a cautious person who is prone to dwelling on mistakes. I would gladly exchange a few false positives for the peace of mind that knowing my breasts are fine from year-to-year will bring me. But not all women feel that way. My friend Catherine, who works in public health, said she’s refused mammograms thus far despite the recommendations of her gynecologist. She told me, “I’ve had a ton of radiation in my life, I have a lot of test anxiety, and I have no history of breast cancer in my family. So given the numbers, I’m going to wait until I’m 45.”

Many women will likely do what their own provider recommends, and Cunningham said it’s unlikely that health-care providers will change their advice based on the ACS guidelines. If the medical expert community, including ACOG or the USPSTF follows suit, however, that shift may trickle down.

Cunningham, for one, said he will continue to recommend mammograms beginning at age 40. He pointed out: “ACS’ own discussion says there’s no question that screening mammography reduces mortality—we just can’t quantify how much it reduces mortality but it could be as high as 20 percent. How can you say that’s not beneficial?”

In fact, he said of the JAMA article, “I read it and I think you could come up with your own conclusion. My own conclusion is you just proved to me I should be doing it more.”

One thing that everyone seems to agree on is the need for tests that are more accurate than mammograms, and new ways to determine risk factors so that those tests can be targeted at women most likely to get breast cancer. Unfortunately, these may be years away. And for now, many women, and even health-care providers, are confused.

Etzioni said, though, that this could be a good teachable moment. “People don’t understand the point that screening has limitations and they have a lot of anxiety” about cancer. This, she said, is “understandable, but this is a great opportunity to educate people.” She added, “The guidelines provide guidance and control to do what they feel will work best for them.”